Jaguar Health Inc (JAGX)

$2.58 +0.01 (0.39%)
Market Cap 2.63M
Revenue (ttm) 11.69M
Net Income (ttm) -38.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -329.26%
Debt to Equity Ratio 22.20
Volume 17,800
Avg Vol 163,842
Day's Range N/A - N/A
Shares Out 1.02M
Stochastic %K 17%
Beta 0.56
Analysts Strong Sell
Price Target $16.00

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 371 8300
Address:
200 Pine Street, Suite 400, San Francisco, United States
PennyStockChasers
PennyStockChasers Jul. 5 at 11:37 PM
$JAGX Float is small , can run nicely
0 · Reply
profitingstocks
profitingstocks Jul. 3 at 1:27 PM
$JAGX i’m not inciting violence but how is Lisa just walking around every day like normal after stealing tens of millions of dollars from people?
0 · Reply
Torobravo_1
Torobravo_1 Jul. 3 at 1:14 PM
$JAGX big run is approaching
1 · Reply
LubeGehrig
LubeGehrig Jul. 3 at 1:13 PM
$SPY You still Bullish on $JAGX? 🤣🤣
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Jul. 3 at 12:41 PM
$JAGX company is criminal
0 · Reply
itiswhatitis999
itiswhatitis999 Jul. 2 at 6:17 PM
$JAGX this took my money
1 · Reply
frittenpit2019
frittenpit2019 Jul. 2 at 4:03 PM
$JAGX 52 W High $110.75 Now $2.55 - what does that mean? Should I invest in this brilliant stock? What a trash.
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Jul. 1 at 9:26 PM
$JAGX down to $1.58, then $0.00
1 · Reply
Zackpedia
Zackpedia Jul. 1 at 12:56 PM
$JAGX Going there
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 10:57 AM
$WOLF $JAGX is for ...... $PWM but u will get it later wolf !
0 · Reply
Latest News on JAGX
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 30, 2025, 9:00 AM EDT - 6 days ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jun 26, 2025, 9:00 AM EDT - 10 days ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jun 25, 2025, 9:00 AM EDT - 11 days ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jun 24, 2025, 4:15 PM EDT - 12 days ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jun 23, 2025, 9:00 AM EDT - 13 days ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Jun 17, 2025, 9:00 AM EDT - 19 days ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jun 11, 2025, 10:00 AM EDT - 25 days ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 9, 2025, 4:15 PM EDT - 27 days ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jun 9, 2025, 9:00 AM EDT - 27 days ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 6, 2025, 9:00 AM EDT - 4 weeks ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2025, 8:00 AM EDT - 6 weeks ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

May 20, 2025, 9:15 AM EDT - 6 weeks ago

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:43 PM EDT - 7 weeks ago

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

Jaguar Health Reports First Quarter 2025 Financials

May 15, 2025, 2:30 PM EDT - 7 weeks ago

Jaguar Health Reports First Quarter 2025 Financials

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

May 14, 2025, 9:00 AM EDT - 7 weeks ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

May 8, 2025, 9:30 AM EDT - 2 months ago

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

May 7, 2025, 9:15 AM EDT - 2 months ago

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

Apr 30, 2025, 8:15 AM EDT - 2 months ago

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Apr 29, 2025, 4:15 PM EDT - 2 months ago

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

Apr 28, 2025, 8:15 AM EDT - 2 months ago

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Apr 17, 2025, 9:00 AM EDT - 2 months ago

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Apr 15, 2025, 9:30 AM EDT - 2 months ago

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Apr 8, 2025, 8:30 AM EDT - 3 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 4, 2025, 4:15 PM EDT - 3 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Apr 1, 2025, 4:15 PM EDT - 3 months ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 9:57 AM EDT - 3 months ago

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Mar 28, 2025, 9:00 AM EDT - 3 months ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

Mar 27, 2025, 8:30 AM EDT - 3 months ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Mar 26, 2025, 11:00 AM EDT - 3 months ago

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

Mar 26, 2025, 9:25 AM EDT - 3 months ago

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

Jaguar Health, Inc. Announces Reverse Stock Split

Mar 18, 2025, 8:30 AM EDT - 3 months ago

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Mar 13, 2025, 4:15 PM EDT - 4 months ago

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Feb 27, 2025, 8:30 AM EST - 4 months ago

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Feb 19, 2025, 9:00 AM EST - 4 months ago

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

Feb 18, 2025, 9:00 AM EST - 4 months ago

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Feb 13, 2025, 9:05 AM EST - 5 months ago

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Feb 6, 2025, 10:00 AM EST - 5 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Feb 3, 2025, 9:30 AM EST - 5 months ago

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jan 29, 2025, 8:30 AM EST - 5 months ago

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

Jan 22, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

Jan 8, 2025, 8:30 AM EST - 6 months ago

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Jan 7, 2025, 10:00 AM EST - 6 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Dec 19, 2024, 9:00 AM EST - 7 months ago

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

Dec 18, 2024, 10:00 AM EST - 7 months ago

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera

Dec 17, 2024, 8:30 AM EST - 7 months ago

FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Dec 13, 2024, 10:00 AM EST - 7 months ago

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Dec 12, 2024, 9:00 AM EST - 7 months ago

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

Dec 9, 2024, 10:00 AM EST - 7 months ago

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

Dec 6, 2024, 8:30 AM EST - 7 months ago

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

PennyStockChasers
PennyStockChasers Jul. 5 at 11:37 PM
$JAGX Float is small , can run nicely
0 · Reply
profitingstocks
profitingstocks Jul. 3 at 1:27 PM
$JAGX i’m not inciting violence but how is Lisa just walking around every day like normal after stealing tens of millions of dollars from people?
0 · Reply
Torobravo_1
Torobravo_1 Jul. 3 at 1:14 PM
$JAGX big run is approaching
1 · Reply
LubeGehrig
LubeGehrig Jul. 3 at 1:13 PM
$SPY You still Bullish on $JAGX? 🤣🤣
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Jul. 3 at 12:41 PM
$JAGX company is criminal
0 · Reply
itiswhatitis999
itiswhatitis999 Jul. 2 at 6:17 PM
$JAGX this took my money
1 · Reply
frittenpit2019
frittenpit2019 Jul. 2 at 4:03 PM
$JAGX 52 W High $110.75 Now $2.55 - what does that mean? Should I invest in this brilliant stock? What a trash.
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Jul. 1 at 9:26 PM
$JAGX down to $1.58, then $0.00
1 · Reply
Zackpedia
Zackpedia Jul. 1 at 12:56 PM
$JAGX Going there
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 10:57 AM
$WOLF $JAGX is for ...... $PWM but u will get it later wolf !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 10:56 AM
$WOLF 0.49 is LISA $JAGX !
0 · Reply
SmallCapAlert
SmallCapAlert Jul. 1 at 8:28 AM
Watchlist: $LTELF AI defense solutions https://www.lstelcom.com/en/applications-use-cases/artificial-intelligence-solutions/ Marketcap: $27 million $JAGX Marketcap: $3.31 million $FAAS Marketcap: $38 million $AITX Marketcap: $22 million $ARTL Marketcap: $4 million
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Jul. 1 at 8:02 AM
$JAGX https://jaguarhealth.gcs-web.com/node/15311/html
0 · Reply
CashMoneyGlitch
CashMoneyGlitch Jun. 30 at 8:52 PM
Can we see a massive run of SQFT into close? Stay tuned bulls! SQFT has only 500k shares outstanding! Momentum breakout on SQFT now! Don't miss out! Could be the next 300% low float mania gapper! $JAGX $HCTI $ALZN $BBAI go
1 · Reply
JaguarHealthInc
JaguarHealthInc Jun. 30 at 1:18 PM
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient https://bit.ly/3I7UHgB $JAGX
0 · Reply
GoDeepinBashersMom
GoDeepinBashersMom Jun. 29 at 6:11 AM
$JAGX lol, I am about to short this stock, this is nonstop falling
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Jun. 27 at 8:43 PM
$JAGX https://jaguarhealth.gcs-web.com/node/15291/html
1 · Reply
MarketManStockWizzard
MarketManStockWizzard Jun. 27 at 8:14 PM
$JAGX i will alert the troops when its time. Meanwhile, its running the wrong way.
0 · Reply
rrrc
rrrc Jun. 27 at 7:52 PM
$JAGX I am ashamed to have bought this worst stock on earth,a real scam led by CEO and management who have no shame in leading this disaster to ground
0 · Reply
SmartestMoney
SmartestMoney Jun. 27 at 6:57 PM
$JAGX 👎🏻
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Jun. 27 at 4:34 PM
$JAGX p3 results have been beaten to death. Now its back to dog shyt canalevia.
0 · Reply
Retail_Warrior
Retail_Warrior Jun. 27 at 3:26 PM
$JAGX
0 · Reply